Affiliation:
1. Department of Anesthesiology, Stony Brook Medicine, 101 Nicolls Rd, Stony Brook, NY 11794, USA
Abstract
The prevalence of patients on buprenorphine therapy presenting for elective surgery has increased. Buprenorphine is a widely used medication for the management of patients with chronic pain. It is also used as maintenance therapy for patients with a history of opioid use disorder (OUD). Due to the lack of a standardized protocol for managing patients on buprenorphine perioperatively, we performed a retrospective analysis to compare pain score outcomes and postoperative opiate requirements between patients who continued buprenorphine versus patients who discontinued buprenorphine. We identified 35 patients: 11 continued buprenorphine and 24 discontinued buprenorphine. The average Post-Anesthesia Care Unit (PACU) pain score was 5.59 for those who continued buprenorphine and 7.54 for those who discontinued preoperative buprenorphine (p value 0.0339). The average postoperative morphine milligram equivalent (MME) use was 86.13 for those who continued preoperative buprenorphine and 107.70 for those who discontinued buprenorphine (p value 0.6439). The results from our study correlate with several previous studies, which showed lower PACU pain scores in patients who continued buprenorphine. There is a benefit of decreased postoperative pain when preoperative buprenorphine is continued, and a decreased possibility for relapse in those with a history of OUD.
Reference16 articles.
1. Current State of Perioperative Buprenorphine Management—A National Provider Survey;Quaye;J. Addict. Med.,2023
2. Perioperative Management of Patients on Buprenorphine and Methadone: A Narrative Review;Sritapan;Balk. Med. J.,2020
3. Buprenorphine management in the perioperative period: Educational review and recommendations from a multisociety expert panel;Kohan;Reg. Anesth. Pain Med.,2021
4. Evidence for Continuing Buprenorphine in the Perioperative Period;Li;Clin. J. Pain,2020
5. Buprenorphine Treatment for Opioid Use Disorder: An Overview;Shulman;CNS Drugs,2019